Evidence map›Paper›PMID 38263073›Full record

Trial reportAlzheimer's research & therapy2024

Subclinical epileptiform activity in the Alzheimer continuum: association with disease, cognition and detection method.

Amber Nous, Laura Seynaeve, Odile Feys, Vincent Wens, Xavier De Tiège, Pieter Van Mierlo, Amir G Baroumand, Koenraad Nieboer, Gert-Jan Allemeersch, Shana Mangelschots and 13 more

Registry-linked trialOpen access · goldAbstract readClinical Trial
In one paragraph

Trial report in Alzheimer's research & therapy, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT04131491 (Epilepsy in Alzheimer's Disease), which is not on this map. Cited by 15 papers.

0numbers the graph read from it
0cells of the map it votes in
15citing papers in PubMed
12.3field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT04131491 naunknown statusnot on this map

Epilepsy in Alzheimer's Disease: Effect on Disease Progression

TypeinterventionalSponsorUniversitair Ziekenhuis BrusselRan2020 to 2023Enrolled80ConditionsMild Cognitive Impairment, Alzheimer DiseaseArmsLumbar puncture
3 · Its place in the literature

Who cites it

15 citing papers in PubMed, 32 citations in OpenAlex.

  1. Article
  2. Review
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Article
  11. Article
  12. Article
  13. Article
  14. Review
  15. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

23 authors at 8 institutions in 1 country.

Amber NousDepartment of Neurology, Universitair Ziekenhuis Brussel (UZ Brussel), Brussels, Belgium.
Laura SeynaeveDepartment of Neurology, Universitair Ziekenhuis Brussel (UZ Brussel), Brussels, Belgium.
Odile FeysDepartment of Neurology, Université Libre de Bruxelles (ULB), Hôpital Universitaire de Bruxelles (HUB), Hôpital Erasme, Brussels, Belgium.
Vincent WensLaboratoire de Neuroimagerie Et Neuroanatomie Translationnelles (LN2T), Université Libre de Bruxelles (ULB), ULB Neuroscience Institute (UNI), Brussels, Belgium.
Xavier De TiègeLaboratoire de Neuroimagerie Et Neuroanatomie Translationnelles (LN2T), Université Libre de Bruxelles (ULB), ULB Neuroscience Institute (UNI), Brussels, Belgium.
Pieter Van MierloEpilog NV, Ghent, Belgium.
Amir G BaroumandEpilog NV, Ghent, Belgium.
Koenraad NieboerDepartment of Radiology, Universitair Ziekenhuis Brussel, Vrije Universiteit Brussel, Brussels, Belgium.
Gert-Jan AllemeerschDepartment of Radiology, Universitair Ziekenhuis Brussel, Vrije Universiteit Brussel, Brussels, Belgium.
Shana MangelschotsNeuroprotection and Neuromodulation (NEUR) Research Group, Center for Neurosciences, Vrije Universiteit Brussel, Laarbeeklaan 103, Brussels, Belgium.
Veronique MichielsDepartment of Neurology, Universitair Ziekenhuis Brussel (UZ Brussel), Brussels, Belgium.
Julie van der ZeeDepartment of Biomedical Sciences, Universiteit Antwerpen, Antwerp, Belgium.
Christine Van BroeckhovenDepartment of Biomedical Sciences, Universiteit Antwerpen, Antwerp, Belgium.
Annemie RibbensIcometrix, Louvain, Belgium.
Ruben HoubrechtsIcometrix, Louvain, Belgium.
Sara De WitteDepartment of Neurology, Universitair Ziekenhuis Brussel (UZ Brussel), Brussels, Belgium.
Mandy Melissa Jane WittensNeuroprotection and Neuromodulation (NEUR) Research Group, Center for Neurosciences, Vrije Universiteit Brussel, Laarbeeklaan 103, Brussels, Belgium.
Maria BjerkeNeuroprotection and Neuromodulation (NEUR) Research Group, Center for Neurosciences, Vrije Universiteit Brussel, Laarbeeklaan 103, Brussels, Belgium.
Caroline VanlersbergheDepartment of Anaesthesiology and Perioperative Medicine, Universitair Ziekenhuis Brussel (UZ Brussel), Brussels, Belgium.
Sarah CeyssensDepartment of Nuclear Medicine, Universitair Ziekenhuis Antwerpen, University of Antwerp, Antwerpen, Belgium.
Guy NagelsDepartment of Neurology, Universitair Ziekenhuis Brussel (UZ Brussel), Brussels, Belgium.
Ilse Smolders *Laboratory of Pharmaceutical Chemistry, Drug Analysis and Drug Information (FASC), Research Group Experimental Pharmacology (EFAR), Center for Neurosciences, Vrije Universiteit Brussel (VUB), Brussels, Belgium.
Sebastiaan Engelborghs *Department of Neurology, Universitair Ziekenhuis Brussel (UZ Brussel), Brussels, Belgium. Sebastiaan.Engelborghs@vub.be.
Universitair Ziekenhuis Brussel · BEVrije Universiteit Brussel · BEUniversity of Antwerp · BEGhent University · BEIcometrix (Belgium) · BEUniversité Libre de Bruxelles · BEErasmus Hospital · BEVIB-UAntwerp Center for Molecular Neurology · BE

Funding

Fonds Wetenschappelijk Onderzoek 1805620NFonds Wetenschappelijk Onderzoek B040419N
6 · The paper itself

Abstract

backgroundEpileptic seizures are an established comorbidity of Alzheimer's disease (AD). Subclinical epileptiform activity (SEA) as detected by 24-h electroencephalography (EEG) or magneto-encephalography (MEG) has been reported in temporal regions of clinically diagnosed AD patients. Although epileptic activity in AD probably arises in the mesial temporal lobe, electrical activity within this region might not propagate to EEG scalp electrodes and could remain undetected by standard EEG. However, SEA might lead to faster cognitive decline in AD.

aims1. To estimate the prevalence of SEA and interictal epileptic discharges (IEDs) in a well-defined cohort of participants belonging to the AD continuum, including preclinical AD subjects, as compared with cognitively healthy controls. 2. To evaluate whether long-term-EEG (LTM-EEG), high-density-EEG (hd-EEG) or MEG is superior to detect SEA in AD. 3. To characterise AD patients with SEA based on clinical, neuropsychological and neuroimaging parameters.

methodsSubjects (n = 49) belonging to the AD continuum were diagnosed according to the 2011 NIA-AA research criteria, with a high likelihood of underlying AD pathophysiology. Healthy volunteers (n = 24) scored normal on neuropsychological testing and were amyloid negative. None of the participants experienced a seizure before. Subjects underwent LTM-EEG and/or 50-min MEG and/or 50-min hd-EEG to detect IEDs.

resultsWe found an increased prevalence of SEA in AD subjects (31%) as compared to controls (8%) (p = 0.041; Fisher's exact test), with increasing prevalence over the disease course (50% in dementia, 27% in MCI and 25% in preclinical AD). Although MEG (25%) did not withhold a higher prevalence of SEA in AD as compared to LTM-EEG (19%) and hd-EEG (19%), MEG was significantly superior to detect spikes per 50 min (p = 0.002; Kruskall-Wallis test). AD patients with SEA scored worse on the RBANS visuospatial and attention subset (p = 0.009 and p = 0.05, respectively; Mann-Whitney U test) and had higher left frontal, (left) temporal and (left and right) entorhinal cortex volumes than those without.

conclusionWe confirmed that SEA is increased in the AD continuum as compared to controls, with increasing prevalence with AD disease stage. In AD patients, SEA is associated with more severe visuospatial and attention deficits and with increased left frontal, (left) temporal and entorhinal cortex volumes.

trial registrationClinicaltrials.gov, NCT04131491. 12/02/2020.

Indexed as

Alzheimer DiseaseCognitive DysfunctionAmyloidogenic ProteinsCognitionDisease ProgressionHumansAmyloidogenic ProteinsAlzheimer’s diseaseHigh-density electroencephalographyInterictal epileptic dischargesLong-term electroencephalographyMagnetoencephalographySubclinical epileptiform activity

Identifiers

PMID38263073
PMCPMC10804650
OpenAlexW4391140622

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.